23 Jul, 2026
According to Straits Research, the global TMJ disorders market size was valued at $614.11 million in 2025 and is projected to grow from $641.01 million in 2026 to $903.24 million by 2034, registering a CAGR of 4.38% during the forecast period 2026–2034.
Temporomandibular disorders, or TMD, are a collection of musculoskeletal and neuromuscular illnesses that affect the temporomandibular joint (TMJ) and the surrounding muscles and bones. TMJ diseases, also known as temporomandibular joint and muscle disorders, are widespread. Due to this condition, the jaw joint and the muscles governing jaw movement become dysfunctional and painful. Typical symptoms include jaw discomfort or dysfunction, earaches, headaches, and facial pain.
TMJ issues are the second most prevalent cause of pain and disability in the musculoskeletal system. TMJ disorders are more prevalent in women than men, with a peak incidence between 20 and 40. In addition, women who use oral contraceptives or additional estrogen are more likely to seek medical care for these conditions. Consequently, the increasing prevalence of these illnesses in these populations drives market expansion. Several research studies examining the prevalence of TMJ diseases are predicted to stimulate market expansion. The practices, particularly thumb sucking, nail biting, mouth breathing, and jaw clenching, were statistically related to TMD. Such studies contribute to the market expansion of TMJ diseases.
There is a growing demand for non-invasive treatment methods that use pharmacotherapy, such as nonsteroidal anti-inflammatory medications (NSAIDS), antidepressants, benzodiazepines, muscle relaxants, and anticonvulsants. According to a 2018 Journal of the Korean Association of Oral and Maxillofacial Surgeons article on TMJ diseases, NSAIDs and benzodiazepines are the most common pharmacologic treatments for TMJ disorders with significant demand. By reducing fatigue, overload, and the release of inflammatory components in masticatory muscles and the TMJ, nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce peripheral sensitivity and alleviate pain. Increasing demand for these non-invasive treatment techniques is a lucrative opportunity for medication producers, stimulating market expansion.
Americas is the most significant shareholder in the global TMJ disorders market and is anticipated to grow at a CAGR of 4.32% during the forecast period. This growth is expected to continue and can be ascribed to the region's high disease prevalence and the introduction and rapid uptake of innovative treatments. According to a study published by the US Department of Health and Human Services, the National Institutes of Health estimates that more than ten million Americans suffer from TMJ disorders. According to the American Hospital Association (AHA), in 2017, there were 6,210 hospitals in the United States. Factors such as the increasing number of hospitals and clinics and the quick adoption of new technology by minor and significant clinics drive this region's market.
Europe is estimated to grow at a CAGR of 3.91% over the forecast period. Europe represented the second-largest share of the TMJ problem market in 2021 due to the region's high healthcare spending and well-developed medical industry. The availability of innovative diagnostic and therapeutic solutions also contributes considerably to the development of this industry. Further, an ongoing study by medical research facilities and academic institutions is discovering new, effective treatments for this illness. Other factors, such as rising healthcare expenditures and more insurance coverage, drive regional market expansion. According to Euro Stat, EU Member States France, Germany, and Sweden spent between 11.0% and 11.3% of their total GDP on healthcare in 2017. In addition, healthcare expenditures in Germany totaled 369 billion euros in 2017. In contrast, France had the second-highest healthcare expenditures with around 260 billion euros, followed by Italy with 153 billion euros and Spain with 103 billion euros.
sales@straitsresearch.com